source
- Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelicsEli Lilly’s proposed acquisition of AtaiBeckley is “the clearest strategic validation to date” of psychedelics as an emerging pharmaceutical category, according to H.C. Wainwright. The analyst caut…BioSpace · 10d ago↗ source
- ‘There is always a first’: Why US biotech Axiom will begin its IPO journey in Hong KongAxiom Biosciences intends to pursue an IPO on the Hong Kong Stock Exchange (HKEX), followed by a co-listing on the Nasdaq—a strategy the company claims is the first U.S. biotech to use.Fierce Biotech · 11d ago↗ source
- FDA’s radical transparency policy for rejections runs into legal uncertaintyHaving started to publish CRLs without consulting the public, the FDA is under pressure to change course amid concerns it failed to openly and fully evaluate a complex issue.